Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Arezzo – page 70

1 011 clinical trials in Arezzo, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Arezzo at a glance
1 011
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 011 trials in Arezzo

Open in trial search

Mantle cell lymphoma

Not recruiting

Study of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:BeOne Medicines AG

Gastrointestinal melanoma+7

Not recruiting

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Pfizer Inc.

Von Willebrand's disease

Not recruiting

Study on the Effectiveness and Safety of Vonicog Alfa with or without Octocog Alfa for Children with Severe von Willebrand Disease Experiencing Bleeding or Undergoing Surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Octocog Alfa
  • Sponsor:Baxalta Innovations GmbH

Dry age-related macular degeneration

Not recruiting

Study of Danicopan for Patients with Geographic Atrophy Due to Age-Related Macular Degeneration

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Danicopan
  • Sponsor:Alexion Pharmaceuticals Inc.

Haemophilia

Not recruiting

Study of Fitusiran for Preventing Bleeding in Boys Aged 1 to 12 with Hemophilia A or B

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Fitusiran
  • Sponsor:Genzyme Corp.

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan, Durvalumab, and Carboplatin for Advanced Non-Small Cell Lung Cancer in Patients Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study on Long-Term Safety and Tolerability of Iptacopan for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Cholangiocarcinoma

Not recruiting

Study of Durvalumab with Gemcitabine and Cisplatin for Patients with Advanced Biliary Tract Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:AstraZeneca AB

Hepatocellular carcinoma

Not recruiting

Study of Durvalumab, Tremelimumab, and Bevacizumab for Patients with Non-Resectable Liver Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Klinikum der Universitaet Muenchen AöR

Non-small cell lung cancer

Not recruiting

Study of Durvalumab with Radiation Therapy for Patients with Early Stage Non-Small Cell Lung Cancer and Osimertinib for Those with EGFR Mutation

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Advanced systemic mastocytosis

Not recruiting

Study on the Safety and Effectiveness of Bezuclastinib for Patients with Advanced Systemic Mastocytosis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Cogent Biosciences Inc.

Myelodysplastic syndrome

Not recruiting

Study of Tamibarotene and Azacitidine Treatment in Newly Diagnosed Adults with RARA-positive Higher-risk Myelodysplastic Syndrome (MDS)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Syros Pharmaceuticals Inc.

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Arezzo

What the registry says about research in the country

01 Urological Oncology

Extensive research focusing on bladder cancer treatments, including innovative therapies combining immunotherapy with established treatments. Studies evaluate new approaches for both muscle-invasive and non-muscle invasive disease.

  • Bladder Cancer Immunotherapy
  • Urothelial Carcinoma Treatment
  • BCG Combination Therapies

Multiple trials exploring targeted treatments for patients with various stages of disease progression.

02 Prostate Cancer Research

Advanced studies examining new therapeutic approaches for metastatic prostate cancer, including novel drug combinations and targeted therapies for specific genetic mutations.

  • Castration-resistant Disease
  • Targeted Molecular Therapies
  • Hormone-based Treatments

Investigating innovative treatment sequences and combinations to improve patient outcomes.

03 Kidney Cancer Innovations

Cutting-edge research in renal cell carcinoma treatment, exploring immunotherapy combinations and targeted approaches for both early-stage and metastatic disease.

  • Immunotherapy Combinations
  • Targeted Molecular Agents
  • Advanced Disease Management

Focus on improving survival rates through novel therapeutic strategies.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.